Substance use, especially alcoholism, has been recognized as a significant problem in schizophrenic patients, though only a few studies on the effects of pharmacotherapy in these patients have been conducted so far. The thioxanthene neuroleptic flupenthixol, which can be given intramuscularly (i.m.) for improving compliance, has been studied as a possible anti-craving drug both in animal models of alcoholism and some clinical studies. Pilot studies suggest that comorbid schizophrenics with substance use may benefit from treatment with flupenthixol. Efficacy of flupenthixol (10-60 mg i.m.) in reducing alcohol consumption of dual diagnosis patients was studied in an open 6-month clinical trial in 27 schizophrenics with comorbid alcoholism. Twenty-one patients entered the intention-to-treat analysis. Fourteen subjects were completers, 13 dropped out. Six patients completely abstained from alcohol during treatment. Alcohol consumption was significantly reduced compared to baseline (4 weeks before treatment as measured by timeline follow-back interview). In general, while patients showed a marked improvement concerning alcohol consumption, only a slight improvement in psychopathology was recorded. Overall tolerability was good. These data indicate a probable beneficial effect of flupenthixol in schizophrenic patients with comorbid alcoholism. Although the efficacy of flupenthixol as an anti-craving drug in dual diagnosis patients has to be explored in further studies, the drug may be considered a promising medication for these patients.
tively high for cannabis and cocaine [49] . Clear evidence for a significant comorbidity of alcoholism and schizophrenia comes especially from the Epidemiological Catchment Area Study, which reported a 4-fold increased risk for alcoholism in schizophrenia [24, 56] . Clinical studies indicate dual diagnosis schizophrenics to have a poor prognosis, notorious noncompliance, a young age of onset, male sex and severe social impairment, among others [35, 36, 65] .
There is no consistent etiological theory to explain substance use in schizophrenia [47] . Apart from the self-medication hypothesis [30, 37] , the role of neuroleptic side effects, social variables and specific neurobiological hypothesis (dysregulated neural integration of dopamine and glutamate signaling in the nucleus accumbens) have been stressed [8] . None of these hypotheses has been generally accepted.
The pharmacotherapy of comorbid schizophrenics with alcoholism has widely been neglected, and very few prospective controlled clinical trials have been performed to date [61, 66, 78] . The use of novel antipsychotics in the treatment of dual diagnosis patients has been advocated repeatedly [4] , but few studies have been conducted so far [11, 79] . The role of other antipsychotics in relapse prevention of substance use in schizophrenia and the interrelationship between changes in psychopathology and substance use in dual diagnosis patients has not been studied in great detail. The thioxanthene neuroleptic flupenthixol, a drug with mixed dopamine D1/D2 antagonistic properties as well as antagonistic properties at the serotonin 5-HT 2A receptors [19, 40, 45] , which is widely used for acute and long-term treatment of schizophrenia [20] , has been studied as a possible anti-craving drug in a number of preclinical and clinical studies.
A broad number of preclinical and animal data suggest flupenthixol to attenuate the positive reinforcing and discriminative stimulus effects of cocaine [74] , to decrease cocaine intake in rats [31, 43] and to block the discriminative stimulus and reinforcing effects of cocaine [52] . With respect to alcohol, animal data in rats also suggest a reduction of alcohol intake [70] . Flupenthixol has been successfully studied in the US as an anti-craving drug in cocaine/ crack consumers [17, 18, 29] . Positive effects of flupenthixol on alcohol as well as other drug intake have been reported in a uncontrolled study on 20 patients who received a daily dose of 0.5-1 mg flupenthixol on a shortterm basis [53] . However, a recently finished placebo-controlled study in nonpsychotic alcoholics (flupenthixol decanoate 10 mg every 14 days) showed unfavorable results [77] .
More specifically, a beneficial effect of flupenthixol decanoate in dual diagnosis schizophrenics has been reported in a case report [71] and an open clinical trial [58] . More recently, Levin et al. [39] studied flupenthixol decanoate (40 mg every 14 days) in schizophrenic patients who were also cocaine users (n = 8) and demonstrated increases in cocaine-negative urine analysis, as well as improved psychopathology (decrease in negative and depressive symptoms).
We report the results of an open controlled clinical trial to assess possible anti-craving and relapse prevention effects of flupenthixol in schizophrenic patients with comorbid alcohol use.
Methods
This was an open exploratory multicenter 6-month trial without a control group to investigate the relapse prevention and antipsychotic efficacy of flupenthixol decanoate in schizophrenic patients with secondary alcohol abuse or dependency. The primary objective was to investigate whether a reduction in the average consumption of alcohol can be achieved by treatment with flupenthixol decanoate. The primary efficacy variable was the average quantity of alcohol consumption during treatment with flupenthixol decanoate as compared to the 4 weeks prior to study entry, measured with the timeline follow-back interview [TFLB; 63]. The study was conducted from July 1997 through December 1999 in 6 psychiatric hospitals in Germany and Switzerland. Patients were seen on a 4-week basis at seven times throughout the trial [visit 1 (V1) took place in week 0, visit 7 (V7) in week 24).
Inclusion Criteria
Patients had to meet the ICD-10 diagnostic criteria for schizophrenia (F 20.0-20.09), be aged between 20 and 55 years and had to have suffered from moderate to severe alcohol dependence for at least 2 years (F 10.2). Successful completion of detoxification (no withdrawal symptoms at baseline) 2 weeks before entering the trial, negative drug screening, written informed consent, and normal EEG and ECG readings were also required. At baseline the Munich Alcoholism Screening Test (MALT) was administered to verify diagnosis of alcohol dependence [14] .
Exclusion Criteria
Psychiatric disorders not consistent with the diagnosis of schizophrenia and concurrent alcohol dependence, neoplasm within the past 5 years, treatment with flupenthixol in the 3 months prior to the study, known intolerability of the drug or contraindication of treatment with flupenthixol, administration of long-acting depot neuroleptics 4 weeks prior to treatment (haloperidol decanoate: 8 weeks), abuse of or dependence on other drugs in the last year preceding treatment, clinically relevant medical or neurological disorders requiring long-term therapy, e.g. insulin-dependent diabetes, severe impairment of liver function (coagulopathy), advanced liver cirrhosis, severe cardiac or pulmonary diseases, renal failure, no fixed address, concomitant treatment with the following medications: unregistered medications, all psychoactive, including anticonvulsive drugs (exceptions: biperiden, promethazine and/or lormetazepame for sleep disorders, lorazepam for anxiety, antidepressants if necessary) or medication for treatment of alcoholism including acamprosate, naltrexone, clomethiazole were exclusion criteria. Patients who were scheduled for a standardized inpatient treatment were also excluded from the trial. The study was conducted according to the guidelines of Good Clinical Practice (GCP) and approved by the local Ethics Committees.
Treatment
All subjects were treated with flupenthixol decanoate for a maximum of 24 weeks. Intramuscular injections of the medication were administered every 2 weeks. All 27 subjects enrolled received at least 1 injection. Compliance was assured as the injections were administered by the investigators. The dose could be adjusted individually (between 10 and 60 mg every two weeks) according to clinical demand and the clinician's decision. The medication was provided in ampoules containing 0.5 ml = 10 mg flupenthixol decanoate. The occurrence of a relapse was not an a priori reason for a premature withdrawal from the study.
Compliance
Blood samples were drawn at visits 3 and 7 for the determination of serum concentrations.
Efficacy and Safety Variables
All efficacy and safety variables were assessed on a 4-week basis throughout the trial. A German version of the TFLB protocol [6, 7, 63] was used to assess self-reported alcohol consumption 4 weeks prior to and throughout the trial. In addition, a German version [42, 54] of the Obsessive Compulsive Drinking Scale (OCDS) was used to measure craving [1] .
Psychopathology was assessed with the Positive and Negative Syndrome Scale [PANSS; 28] and the Clinical Global Impression (CGI; NIMH 1976) Scale (secondary variables). Extrapyramidal symptoms were measured by the AIMS scale [22] , changes in social functioning be thy 8-item self-report social functioning questionnaire [SFQ; 75] .
Statistics
Descriptive statistics were used to evaluate the quantitative variables. Alcohol consumption, craving and psychopathological status were analyzed by correlation statistical analyses.
For all quantitative variables, means, standard deviations, minimum, median and maximum were computed. Frequency counts and percentages were generated for qualitative variables. Repeated measurements of some selected variables were analyzed on an exploratory basis using paired t tests. No confirmatory analyses were conducted. All analyses were conducted with the SAS version 6.12 program package.
The intention to treat (ITT) sample included all patients with baseline values, one injection of the study medication and at least 1 follow-up visit. The valid for efficacy (VfE) group completed the study according to protocol. Patients who prematurely terminated the study were included with their last available measurement, which was then used as final outcome. Changes in variables of special interest were analyzed by t test.
Adverse events were classified according to COSTART and grouped according to the body systems affected.
Results
During the recruitment period 27 patients were enrolled in the trial (safety analysis). Twenty-one subjects were included in the ITT, of which 14 subjects (the VfE population) completed the 6-months study period. Thirteen patients were dropouts. Reasons for premature termination were lost to follow-up (n = 7), withdrawal of consent (n = 4), adverse event (severe akathisia; n = 1) and bad compliance (n = 1).
Baseline demographics are given in table 1. Seventeen (63%) of the 27 patients were male, 10 (37%) female. In the VfE group 8 (57%) patients were male, 6 (43%) female. Mean age of the VfE population was 32.0 (23-58) years, BMI was 23.5 (17-29. 3) kg/m 2 . With respect to schizophrenic subtype, most VfE patients were diagnosed as paranoid subtype (n = 12; 86%), 1 patient had a catatonic (7%), another one a schizoaffective psychosis (7%).
All patients showed marked to severe alcohol dependence. For the ITT sample, 5 (SD 1.12) out of the 6 ICD-10 criteria were fulfilled (VfE sample: 5.0 B 1.07). MALT score was 27.64 (B 6.39), indicating severe alcohol dependence.
The 21 ITT patients had had a daily alcohol consumption of more than 150 ml pure alcohol (females: 120 ml) over a period of several months, 12 patients had had a maximum consumption of more than 300 (females: 240) ml on several days a month.
Mean flupenthixol dosage given was 30.4 mg every 2 weeks to the ITT sample (VfE sample: 32.2 mg). Mean duration of treatment in the VfE group was 170 (166-183) days. During treatment with flupenthixol, 10 patients (71%) received short-term concomitant psychopharmacological medication: 6 subjects received biperiden, 6 psycholeptics and 4 were on antidepressants (doxepine, amitryptilin, nefazodone, paroxetine). No switch to benzodiazepines or other drugs of abuse could be detected.
Efficacy
Alcohol Consumption. Fourteen of the 21 patients (60%) of the ITT sample completed the study. Six of them remained completely abstinent throughout the trial, 2 patients reported a reduced consumption during treatment compared to baseline, 3 patients were relapsers at 2 or 3 visits, 3 patients on more than 3 visits. Eight patients were abstinent at study end. Alcohol consumption in standard drinks/day as measured by TFLB decreased significantly over time ( fig. 1 ). In addition, the mean number of relapses to heavy alcohol consumption and the number of Soyka/Aichmüller/v Bardeleben/Beneke/ Glaser/Hornung-Knobel/Wegner drinks per relapse decreased after initiation of treatment ( fig. 2) . In patients who relapsed, the mean number of drinks per relapse dropped from 7.7 (B 5.8) drinks to 4.4 (B 3.2) drinks during the initial study phase and remained reduced throughout the study. The percentage of abstinent days during treatment also increased significantly during treatment ( fig. 3 ). Craving scores, as measured by OCDS, decreased significantly between visits 1 and 2, and continuously remained on a reduced level throughout treatment ( fig. 4) . Psychopathology. General assessment of the VfE subjects as documented in the CGI revealed that at the end of the study 50% were very much or much improved, 21% were unchanged or had slightly worsened. In line with these results, social functioning of the patients as measured by the SFQ had improved by 30%. The mean sum scores of the SFQ decreased from 9.07 (V1) to 6.79 (V2) and ended at 6.18 at V7, indicating an enhanced social functioning.
Results of the PANSS subscales (positive symptoms, negative symptoms, global) and the BPRS score only slightly decreased over time ( fig. 5) .
Safety Analysis. Out of the 27 patients who received at least one injection of study medication, 9 subjects (33%) reported at least 1 adverse event (AE). Six of these individuals suffered from 1 AE, the remaining three had 2, 3 and 5 AEs. In total, 16 adverse events were recorded: akathisia (19%), nervousness (19%), extrapyramidal symptoms (12%), insomnia (6%), neuropathy (6%). Body systems affected were 'body as a whole' (recorded in 25% of AEs) and 'digestive' and 'special senses', recorded in 6%. Of the 16 AEs, 12% were rated as possibly related to study medication, 43% as probably, 37% as improbably related to the medication, and 6% as not assessable.
Extrapyramidal motor side effect rating as assessed with the AIMS was remarkably low. The mean summary scores (items 1-7) decreased from 1.57 (SD 2.65) at baseline to 1.14 [2, 54] at V5 but returned to 1.64 [3, 20] at endpoint (V7). At least 8 subjects of the VfE sample scored zero at all control visits. The mean global assessment score was slightly enhanced from 0.71 (SD 1.20) at baseline to 1.50 [3, 32] at V5 and 1.43 [2, 68] at endpoint.
Two subjects showed a significant adverse event (akathisia or parkinsonoid), the former terminated the study prematurely for this reason. Serum concentrations of flupenthixol measured were rather low and, in some cases, close to the detection limit (0.1 ng/ml) The mean concentration was 0.21 (0.1-0.46) ng/ml (V3) and 0.22 ng/ml (0.1-0.83; V7), respectively.
Discussion
Substance use has been recognized as a major problem, affecting compliance and treatment outcome. A number of dual diagnosis treatment programs has been introduced over the past decade for this newly recognized type of patients [2, 12, 23, 25] , while the pharmacotherapy of these patients has widely been neglected.
The present study was designed to examine possible relapse prevention effects of the thioxanthene flupenthixol in schizophrenics with comorbid alcoholism, and to explore a possible interrelationship between improvement of psychopathology and alcohol use. Twenty-seven patients were included in this 6-month study, 21 patients were eligible for ITT analysis, 13 patients were dropouts. The efficacy data from this study as measured by TLFB [7, 63] showed a significant reduction of alcohol consumption behavior compared to the 4-week baseline period before treatment. Six patients remained completely abstinent throughout the trial. In addition, craving as measured by a visual analogue scale and the OCDS [1, 54] , was markedly decreased following initiation of treatment. Results from this exploratory study should be discussed with caution due to the small number of patients included and the open label design of the study. Limitations also arise from the dropout rate of approximately Soyka/Aichmüller/v Bardeleben/Beneke/ Glaser/Hornung-Knobel/Wegner 50%, which is similar to the dropout rates in pharmacological studies with anti-craving drugs in nonpsychotic alcoholics [67] . In addition, the efficacy of craving scales like the OCDS in predicting relapse in alcoholics has not been firmly established [34] . Still, the overall observed clinical effects seem remarkable, especially in the light of the treatment outcomes and compliance rates in dual diagnosis schizophrenics (cited above). Interestingly, while the antialcoholic effect of flupenthixol could clearly be demonstrated, only a slight improvement in the psychopathology of the substance-using patients could be noticed. The therapeutic effect of flupenthixol did not seem to be related to an overall improvement of psychopathology, thus questioning to some extent the self-medication hypothesis of substance use in schizophrenia [30] . This question deserves further attention. Substance use has been associated with the patients' wish to improve psychopathological symptoms, such as anhedonia [55] , or side effects of neuroleptic treatment. A number of findings question this hypothesis [3] , and the empirical evidence is small [65, 72] .
Two more general aspects may also be generated from this study. First, although the mean dosage given (32 mg/ 14 days) was higher than the one usually given in relapse prevention for schizophrenia [20 mg; 32] , the serum concentrations of flupenthixol measured were lower than those usually found in schizophrenics [26, 27, 73] . Low neuroleptic serum concentrations in alcoholic schizophrenics have also been reported in other studies [64] and may be explained by an accelerated metabolism of the drug in these patients, but this topic warrants further studies. For dual diagnosis patients, measurement of plasma levels can be recommended for verifying compliance or variations in metabolism of neuroleptics.
Second, although dual diagnosis patients are notorious for noncompliance [65, 68] , the dropout rate in this study was not higher than those in pharmacological studies with nonpsychotic alcoholics [33] . Clearly, more pharmacological studies in dual diagnosis patients following a core protocol are needed to explore pharmacological options and risks in these patients.
A consistent theory explaining the apparently increasing number of dual diagnosis patients has not been put forward, but medication effects clearly play a significant role in the development and treatment of substance use in schizophrenia. A number of different pharmacological treatment options can be discussed with respect to substance use in schizophrenia: (1) use of conventional antipsychotics to improve psychopathology, thus reducing the relapse risk in dual diagnosis patients; (2) use of atypical neuroleptics to improve negative symptomatology and avoid side effects, possibly leading to substance use; (3) use of antidepressants or other drugs to improve depression or anhedonia [59, 60, 61] , and (4) use of novel anti-craving drugs, such as acamprosate or naltrexone.
Only the first two options have been addressed in a number of recent studies. To date, the empirical basis for psychopharmacology in dual diagnosis patients is small. The role of 'conventional' neuroleptics in the development and treatment of substance use in schizophrenia has been discussed with some concern. On the one hand researchers have argued them to precipitate or worsen substance use [61, 76] . Dual diagnosis patients may be more prone to the side effects of neuroleptic treatment, such as tardive dyskinesia and, especially, akathisia [10, 13, 57, 62] , while in the present study the incidence of akathisia and extrapyramidal side effects was remarkably low. On the other hand the empirical basis for a beneficial effect of atypic neuroleptics such as clozapine in dual diagnosis patients [44] is very small. Only recently, in a retrospective survey of 43 patients, clozapine was reported to decrease substance use in schizophrenia [79] . In addition Drake et al. [11] , in an a posteriori analysis of 151 patients with schizophrenia or schizoaffective disorder and co-occurring substance use, demonstrated that patients who received clozapine experienced significant reductions in the severity of their alcohol abuse. However, continuous substance use in schizophrenics under treatment with clozapine has been reported in some cases [71] . Since there are no depot formula for atypical neuroleptics yet, the question of noncompliance, crucial for the treatment of dual diagnosis patients, needs to be considered.
The results of this study are not in line with a recently published study by Wiesbeck et al. [77] , who failed to demonstrate a clinical efficacy of flupenthixol in nonpsychotic alcoholics. The dosage of flupenthixol used in their study was much lower than the one used in the schizophrenic patients of the present trial, but differences in treatment outcome may not only be linked to dosage. They may also reflect different neurobiological mechanisms underlying the addiction process in schizophrenic and other alcoholics (e.g., the dopaminergic neurotransmission might function differently). In addiction, tolerability of the drug and side effects may also be different in schizophrenic and nonpsychotic alcoholics.
To date, flupenthixol may be considered to be a promising medication to study in dual diagnosis schizophrenics. In the light of the preclinical evidence, suggesting that relatively low doses of flupenthixol may attenuate alcohol and cocaine intake [70] , further clinical testing of this compound in drug abuse/dependence disorders seems warranted, and should include a control group. Although low doses of flupenthixol can also cause extrapyramidal side effects in some cases [16] , the clinical data available so far suggest that tolerance of flupenthixol is usually good in patients with substance abuse/dependence disorders. This is also supported by data from the present study. Most of the subjects of the ITT sample experienced no or only minimal EPS. Correspondingly, the mean AIMS scores at all visits were rather low. This finding is remarkable in the light of the mean dosage of 32.2 mg/14 days, which is substantially above the recommended dose of 20 mg/14 days used for relapse prevention [32] .
